Skip to main content
Log in

Percutaneous Endovascular Radiofrequency Ablation for Malignant Portal Obstruction: An Initial Clinical Experience

  • Clinical Investigation
  • Published:
CardioVascular and Interventional Radiology Aims and scope Submit manuscript

Abstract

Purpose

The Habib™ VesOpen Catheter is a new endovascular radiofrequency ablation (RFA) device used to treat malignant portal obstruction. The purpose of this study was to evaluate the clinical feasibility and safety of RFA with this device.

Methods

We collected the clinical records and follow-up data of patients with malignant portal obstruction treated with percutaneous endovascular portal RFA using the Habib™ VesOpen Catheter. Procedure-related complications, improvement of symptoms, portal patency, survival, and postoperative biochemical tests were investigated.

Results

The 31 patients enrolled in the study underwent 41 successful endovascular portal RFA procedures. Patients were divided into a portal-stenting (PS) group (n = 13), which underwent subsequent portal stenting with self-expandable metallic stents, and a non-stenting (NS) group (n = 18), which did not undergo stenting. No procedure-related abdominal hemorrhage or portal rupture occurred. Postablation complications included abdominal pain (n = 26), fever (n = 13), and pleural effusion (n = 15). Improvements in clinical manifestations were observed in 27 of the 31 patients. Of the 17 patients experiencing portal restenosis, 10 underwent successful repeat RFA. The rate of successful repeat RFA was significantly higher in the NS group than in the PS group. Median portal patency was shorter in the PS group than in the NS group. No mortality occurred during the 4 weeks after percutaneous endovascular portal RFA.

Conclusions

Percutaneous endovascular portal RFA is a feasible and safe therapeutic option for malignant portal obstruction. Prospective investigations should be performed to evaluate clinical efficacy, in particular, the need to evaluate the necessity for subsequent portal stenting.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Monto A, Wright TL. The epidemiology and prevention of hepatocellular carcinoma. Semin Oncol. 2001;28(5):441–9.

    Article  CAS  PubMed  Google Scholar 

  2. Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology. 2004;127(5 Suppl 1):S35–50.

    Article  PubMed  Google Scholar 

  3. Minagawa M, Makuuchi M. Treatment of hepatocellular carcinoma accompanied by portal vein tumor thrombus. World J gastroenterol. 2006;12(47):7561–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Takizawa D, Kakizaki S, Sohara N, Sato K, Takagi H, Arai H, et al. Hepatocellular carcinoma with portal vein tumor thrombosis: clinical characteristics, prognosis, and patient survival analysis. Dig Dis Sci. 2007;52(11):3290–5. doi:10.1007/s10620-007-9808-2.

    Article  PubMed  Google Scholar 

  5. Abdel-Wahab M, El-Ghawalby N, Mostafa M, Sultan A, El-Sadany M, Fathy O, et al. Epidemiology of hepatocellular carcinoma in lower Egypt Mansoura Gastroenterology Center. Hepato-gastroenterology. 2007;54(73):157–62.

    PubMed  Google Scholar 

  6. Fujii T, Takayasu K, Muramatsu Y, Moriyama N, Wakao F, Kosuge T, et al. Hepatocellular carcinoma with portal tumor thrombus: analysis of factors determining prognosis. Jpn J Clin Oncol. 1993;23(2):105–9.

    CAS  PubMed  Google Scholar 

  7. Rabe C, Pilz T, Klostermann C, Berna M, Schild HH, Sauerbruch T, et al. Clinical characteristics and outcome of a cohort of 101 patients with hepatocellular carcinoma. World J Gastroenterol. 2001;7(2):208–15.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Villa E, Moles A, Ferretti I, Buttafoco P, Grottola A, Del Buono M, et al. Natural history of inoperable hepatocellular carcinoma: estrogen receptors’ status in the tumor is the strongest prognostic factor for survival. Hepatology. 2000;32(2):233–8. doi:10.1053/jhep.2000.9603.

    Article  CAS  PubMed  Google Scholar 

  9. Cohen J, Edelman RR, Chopra S. Portal vein thrombosis: a review. Am J Med. 1992;92(2):173–82.

    Article  CAS  PubMed  Google Scholar 

  10. Macpherson AI. Portal hypertension due to extrahepatic portal venous obstruction. A review of 40 cases. J R Coll Surg Edinb. 1984;29(1):4–10.

    CAS  PubMed  Google Scholar 

  11. Witte CL, Brewer ML, Witte MH, Pond GB. Protean manifestations of pylethrombosis. A review of thirty-four patients. Ann Surg. 1985;202(2):191–202.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Sugiura N, Matsutani S, Ohto M, Ebara M, Yoshikawa M, Yamaguchi T, et al. Extrahepatic portal vein obstruction in adults detected by ultrasound with frequent lack of portal hypertension signs. J Gastroenterol Hepatol. 1993;8(2):161–7.

    Article  CAS  PubMed  Google Scholar 

  13. Yamakado K, Tanaka N, Nakatsuka A, Matsumura K, Takase K, Takeda K. Clinical efficacy of portal vein stent placement in patients with hepatocellular carcinoma invading the main portal vein. J Hepatol. 1999;30(4):660–8.

    Article  CAS  PubMed  Google Scholar 

  14. Giorgio A, de Stefano G, Di Sarno A, Farella N, Giorgio V, Scognamiglio U, et al. Radiofrequency ablation of hepatocellular carcinoma extended into the portal vein: preliminary results. J Ultrasound. 2009;12(1):32–7. doi:10.1016/j.jus.2008.12.004.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Lazoura O, Zacharoulis D, Kanavou T, Rountas C, Katsimboulas M, Tzovaras G, et al. A novel experimental animal model of arterial stenosis based on endovascular radiofrequency energy application. J Investig Surg. 2011;24(3):123–8. doi:10.3109/08941939.2011.557470.

    Article  Google Scholar 

  16. Ministry of Health of the People’s Republic of China. Diagnosis, management, and treatment of hepatocellular carcinoma (V2011). J Clin Hepatol. 2011;27(11):1141–59.

    Google Scholar 

  17. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53(3):1020–2. doi:10.1002/hep.24199.

    Article  PubMed  PubMed Central  Google Scholar 

  18. European Association for the Study of the Liver. EASL–EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56(4):908–43. doi:10.1016/j.jhep.2011.12.001.

    Article  Google Scholar 

  19. Omata M, Lesmana LA, Tateishi R, Chen PJ, Lin SM, Yoshida H, et al. Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int. 2010;4(2):439–74. doi:10.1007/s12072-010-9165-7.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Chuan-Xing L, Xu H, Bao-Shan H, Yong L, Pei-Jian S, Xian-Yi Y, et al. Efficacy of therapy for hepatocellular carcinoma with portal vein tumor thrombus: chemoembolization and stent combined with iodine-125 seed. Cancer Biol Ther. 2011;12(10):865–71. doi:10.4161/cbt.12.10.17676.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Mizandari M, Ao G, Zhang Y, Feng X, Shen Q, Chen M, et al. Novel percutaneous radiofrequency ablation of portal vein tumor thrombus: safety and feasibility. Cardiovasc Interven Radiol. 2013;36(1):245–8. doi:10.1007/s00270-012-0451-8.

    Article  Google Scholar 

  22. Wu TT, Li HC, Li WM, Ao GK, Lin H, Zheng F, et al. Percutaneous intraluminal radiofrequency ablation for malignant extrahepatic biliary obstruction: a safe and feasible method. Dig Dis Sci. 2015;60(7):2158–63. doi:10.1007/s10620-015-3547-6.

    Article  PubMed  Google Scholar 

  23. Yamakado K, Nakatsuka A, Tanaka N, Fujii A, Isaji S, Kawarada Y, et al. Portal venous stent placement in patients with pancreatic and biliary neoplasms invading portal veins and causing portal hypertension: initial experience. Radiology. 2001;220(1):150–6. doi:10.1148/radiology.220.1.r01jl03150.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Wei-Min Li.

Ethics declarations

Conflict of interest

All authors declare that there are no conflicts of interest or current funding sources for this study.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Additional information

Hu-Cheng Li is the co-first author.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wu, TT., Li, HC., Zheng, F. et al. Percutaneous Endovascular Radiofrequency Ablation for Malignant Portal Obstruction: An Initial Clinical Experience. Cardiovasc Intervent Radiol 39, 994–1000 (2016). https://doi.org/10.1007/s00270-016-1317-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00270-016-1317-2

Keywords

Navigation